Ningbo Menovo Pharmaceutical Co., Ltd. (SHSE: 603538)
Health Care · Pharmaceuticals · CN
CN¥28.51
-5.63% today · +46.3% 1Y
Ningbo Menovo Pharmaceutical Co., Ltd. (SHSE: 603538) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.44B and employs 2,370 people.
Over the last twelve months the share price has gained 46.3%, trading between 13.55 and 50.28.
Tweenvest scores Ningbo Menovo Pharmaceutical Co., Ltd. across four factors: quality 59/100, value 34/100, growth 78/100, dividend 40/100. Its strongest factor is growth.
603538 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.44B
- Revenue (TTM)
- $248.00M
- P/E
- 76.48
- EPS
- 0.37
- Dividend yield
- 0.39%
- Beta (5Y)
- -0.17
- 52-week high
- CN¥50.28
- 52-week low
- CN¥13.55
- Avg volume (3M)
- —
- Shares outstanding
- 339.93M
- Employees
- 2,370
- Next earnings
- —
About Ningbo Menovo Pharmaceutical Co., Ltd.
Ningbo Menovo Pharmaceutical Co., Ltd. operates across the full spectrum of pharmaceutical activities, encompassing the research, development, production, and distribution of medicinal products. Their extensive product line features Active Pharmaceutical Ingredients (APIs), intermediate chemicals, and finished drug formulations. These offerings are designed to address a wide range of therapeutic areas, including cardiovascular, central nervous system, respiratory, oncological, anti-infective, digestive, and geriatric disorders, as well as antiviral treatments. The company commenced operations in 2004 and maintains its principal place of business in Ningbo, China.
- ISIN
- CNE100002Y25
- Founded
- 2004
- Listed since
- Apr 10, 2017
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.